Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study, Evaluating the Efficacy of Montelukast in Reducing the Incidence and Severity of Monoclonal Antibodies Associated Infusion Reactions

NCT04198623 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT04198623
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04198623 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study, Evaluating the Efficacy of Montelukast in Reducing the Incidence and Severity of Monoclonal Antibodies Associated Infusion Reactions
Lead sponsor
University of California, San Francisco
Phase
Phase 2
Overall status
Completed
Start date
March 20, 2020
Completion date
July 31, 2024
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

infusion reaction, monoclonal antibody